August 22, 2016 / 1:51 PM / a year ago

BRIEF-Pfizer says Medivation deal will not affect split-up decision

Aug 22 (Reuters) - Pfizer, in analyst conference call:

* Says still plans to decide By late 2016 whether to split itself into separate companies selling either generic, patent-protected drugs

* Says planned Medivation deal will not affect Pfizer decision on whether to split itself

* Says potential earlier use of Medivation’s Xtandi would be key to prostate cancer drug’s growth

* Says remains open to deals of all sizes in future, if financially justified

* Says potential earlier use of Xtandi would open it to urologists, expanding prescriptions

* Says Xtandi is only at beginning of its “growth cycle”

* Says says “while interested” in Medivation’s experimental drugs, value of deal was really based on Xtandi growth potential Source text for Eikon: Further company coverage: (Reporting by Ransdell Pierson)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below